SEC Comment Letter for NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709) (NKTR) — Dec 13, 2021
NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709)
Date: Dec. 13, 2021 · CIK: 0000906709 · Accession: 0000000000-21-014903
AI Filing Summary & Sentiment
File numbers found in text: 000-24006
Letter
United States securities and exchange commission logo December 13, 2021 Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, CA 94158 Re:Nektar Therapeutics Form 10-K for the Fiscal Year Ended December 31, 2020 Filed February 26, 2021 File Number 000-24006 Dear Mr. Labrucherie: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
December 13, 2021
Gil M. Labrucherie
Chief Operating Officer and Chief Financial Officer
Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, CA 94158
Re:Nektar Therapeutics
Form 10-K for the Fiscal Year Ended December 31, 2020
Filed February 26, 2021
File Number 000-24006
Dear Mr. Labrucherie:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences